(Q37717839)

22 August 2017

title

Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience (English)

1 reference

22 August 2017

0 references

3

D Cunningham

1 reference

22 August 2017

C Jackson

1

1 reference

22 August 2017

B Sirohi

2

1 reference

22 August 2017

A Horwich

4

1 reference

22 August 2017

K Thomas

5

1 reference

22 August 2017

A Wotherspoon

6

1 reference

22 August 2017

publication date

23 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

21

1 reference

22 August 2017

issue

10

1 reference

22 August 2017

page(s)

2061-2068

1 reference

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

Epstein-Barr virus in Hodgkin disease. Relation to age and subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. British National Lymphoma Investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

ChlVPP combination chemotherapy for Hodgkin's disease: long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

EPIC: an effective low toxicity regimen for relapsing lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

Breast cancer in women after treatment for Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

Radiotherapy alone for lymphocyte-predominant Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: implications for consolidation radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ063

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ063

1 reference

22 August 2017

1 reference